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Highlights 
 RYR1-related myopathies are associated with functional impairments and chronic 
fatigue 
 This accounts for congenital myopathies and to a lesser extent for malignant 
hyperthermia 
 This results in substantial loss of quality of life 
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Abstract 
Mutations in RYR1 are a common genetic cause of non-dystrophic neuromuscular disorders. To 
obtain baseline data concerning the prevalence of fatigue, the psychological disease burden and 
quality of life associated with these common conditions, we performed a questionnaire study. 
Seventy-two patients were included in this study, 33 with a congenital myopathy and 39 with 
malignant hyperthermia  or exertional rhabdomyolysis. Our results showed that patients with RYR1-
related myopathies have more functional impairments and significant chronic fatigue compared to 
healthy controls, with almost half of patients being severely fatigued. Whilst fatigue, pain and 
associated physical and social difficulties were more pronounced in those with permanent 
phenotypes, individuals with intermittent phenotypes also scored higher in all relevant categories 
compared to healthy controls. These findings indicate that RYR1-related myopathies, despite being 
often considered relatively mild conditions, are nevertheless associated with severe fatigue and 
functional limitations, resulting in substantial loss of quality of life. Moreover, milder but in essence 
similar findings in patients with RYR1-related malignant hyperthermia and rhabdomyolysis suggest 
that those phenotypes are not truly episodic but in fact associated with a substantial permanent 
disease burden. These preliminary data should help to design more comprehensive quality of life 
studies to inform standards of care. 
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Introduction 
Mutations in RYR1, the gene encoding the sarcoplasmic reticulum (SR) type 1 ryanodine receptor 
(RyR1), have emerged as the most common genetic cause of non-dystrophic neuromuscular 
disorders in recent years.[1] RYR1 mutations give rise to a wide variety of myopathies presenting 
throughout life [2], ranging from early-onset congenital myopathies (for review, Jungbluth et al. [3]) 
to episodic manifestations in adulthood such as exertional rhabdomyolysis (RM), malignant 
hyperthermia during anesthesia with susceptibility proven by an in vitro contracture test (MH) and 
periodic paralysis [4] in otherwise healthy individuals. The very wide RYR1-associated clinical 
spectrum is due to the highly variable functional impact of RYR1 mutations on the RyR1 receptor, the 
principal skeletal muscle calcium release channel with a crucial role in excitation-contraction coupling 
(ECC).  
The weakness associated with early-onset RYR1-related congenital myopathies may be considerable 
and pose a substantial disease burden. Although fixed weakness is rare in episodic RYR1-associated 
RM and MH, individuals presenting with these features may nevertheless experience significant 
fatigue and myalgia in between episodes.[5] Myalgia may also be a prominent additional feature in 
early-onset RYR1-related myopathies such as central core disease (CCD), and has been reported in 
these conditions even before their genetic resolution.[6] Moreover, non-skeletal muscle 
manifestations, including an increased bleeding tendency and bowel and bladder symptoms due to 
smooth muscle dysfunction are increasingly recognized, and reflective of RYR1 expression in tissues 
other than striated skeletal muscle.[2, 7-11] These complex disease phenotypes are likely to have a 
substantial impact on the quality of life (QoL) in affected individuals, yet no systematic studies 
investigating the associated fatigue, pain and functional impairments have been performed in RYR1-
related disorders to date. 
To obtain baseline data concerning the functional impairments, fatigue and QoL associated with 
these common conditions, we performed a questionnaire study focussing on these features in 
patients with RYR1-related myopathies throughout the recognized disease spectrum.[2] Standardized 
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questionnaires were used to obtain information on: functional impairments, fatigue, symptoms of 
psychopathology  and other aspects of QoL. We compared patients with RYR1-related myopathies 
with healthy controls and with patients affected by a progressive neuromuscular disorder with 
multisystem involvement, MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-
like episodes,) spectrum disorder. In addition, within the group of patients with RYR1-related 
myopathies, the subgroup of patients with ‘permanent phenotypes’ (congenital myopathies) were 
compared to the patients with ‘episodic phenotypes’ (MH and RM). 
The results of this explorative study will improve management of patients with RYR1-related 
myopathies, and enable the definition of areas in need of further research concerning the disease 
burden associated with these common neuromuscular disorders.  
 
Methods  
Patients 
All patients with a genetically confirmed RYR1-related disorder seen at the Department of Neurology 
(Radboudumc) and the Dutch national referral centre for Malignant Hyperthermia (Canisius-
Wilhelmina Hospital) in Nijmegen, The Netherlands, were approached to participate in this 
descriptive questionnaire study. Additional patients were approached through the Dutch national 
patient organization for myopathies (www.spierziekten.nl) as well as Dutch neuromuscular 
neurologists (www.spierziektencentrum.nl). This resulted in a total of 200 patients being invited 
through a dedicated invitation letter sent to their home addresses. The key neuromuscular features 
of a proportion of these patients have already been reported by Snoeck et al.[2]  
 
Methods 
This study was approved by the regional Ethics Committee: Human Research Committee region 
Arnhem and Nijmegen (CMO 2016-2954). All participants gave written informed consent. 
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After informed consent, patients received an email with a link, which led to the questionnaire in a 
private and secure environment (Radquest 2.0). The patients were asked to open this link and fill in 
the questionnaires at their preferred place and time. Once commenced, the questionnaire had to be 
completed within 24 hours to prevent errors in data storage. If the questionnaire was not completed 
within two weeks, patients received a reminder email. If this neither resulted in completion, a 
reminder phone call followed after a further two weeks. 
 
Questionnaires 
Various aspects of functional impairments, fatigue and QoL were assessed with questionnaires that 
have been used before and validated in neuromuscular disorders.[12, 13] 
 
Functional impairment was assessed using the Sickness Impact Profile (SIP), aimed at assessing 
changes in everyday activities due to sickness and covering the following dimensions of functioning: 
sleep/rest (7 items); home management (10 items); mobility (addressing the ability to move indoors 
and outdoors; 10 items); social interactions (20 items); ambulation (addressing the ability to walk and 
walk stairs, and use of walking aids; 12 items); alertness behaviour (10 items); work (3 items); and 
recreation (8 items).[14, 15] Higher scores reflect more impairment. Scores were compared to a 
group of 83 healthy subjects.[16] 
 
Fatigue severity was assessed with the Checklist Individual Strength (CIS). The CIS is a questionnaire 
with twenty items and the following four subscales: perceived fatigue severity (8 items), 
concentration (5 items), motivation (4 items) and physical activity (3 items). The total score is 
calculated by adding up the scores for each subscale (range = 20-140), with higher scores indicative 
of a higher disease burden.[17] A CIS-fatigue score of 35 or more was used to identify severe fatigue. 
A representative sample from the Dutch general population was used as a reference group.[18] 
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Symptoms of psychopathology were assessed by the SLC-90. This questionnaire consists of 90 
descriptions of complaints on several subscales (agoraphobia, anxiety, depression, somatisation, 
obsessive-compulsive behaviour, interpersonal sensitivity, hostility, sleep). The statements are rated 
on a five-point Likert scale (a psychometric scale commonly involved in questionnaire research with 
scores 1-5; 1: strongly disagree; 2: disagree; 3: neither agree nor disagree; 4: agree; 5: strongly 
agree)[19] Higher scores reflect more symptoms of psychopathology. A total SCL-90 score of more 
than 160 is indicative of high psychological distress, while a score of more than 200 is indicative of a 
psychiatric disorder.[20, 21] 
For additional assessment of anxiety and depression the Hospital Anxiety and Depression Scale 
(HADS), specially developed for the assessment in a hospital population, was used. The HADS 
includes seven items about depression and seven items about anxiety. Its total score can be used as a 
measure of general distress. Total scores ≥ 11 are indicative of high distress.[22] [23] The HADS is 
designed to assess symptoms of depression in people with medical conditions by controlling for vital 
aspects of depression that could easily interfere with symptoms of the disease. 
 
Overall quality of life was assessed using the RAND-SF36 questionnaire. Subscales investigated 
several dimensions of QoL (physical functioning, social functioning, emotional functioning, general 
health status, perceived change in health status, mental health, vitality and pain). Scores range from 
0 (maximum limitations) to 100 (optimal functioning).[24] A commonly used representative sample 
of the Dutch general population (men and women aged 18 to 75 years) was used as a reference 
group.[25]  
 
Statistics. Data analysis was performed using SPSS (version 22). Descriptive statistics were used to 
describe the characteristics of the sample as well as patient reported outcomes on functional 
impairment, fatigue, psychological symptoms, and QoL. Fisher exact test was used to compare the 
response and non-response group (age, sex and phenotype). One-sample t tests were used for the 
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comparison of RYR1-mutated patients with healthy controls, and a sample of patients with a MELAS 
spectrum disorder.[13] ANOVA’s were used to compare permanent with episodic RYR1-related 
phenotypes with regards to patient reported outcomes concerning QoL, functional impairment, 
symptoms of psychopathology , and fatigue. Because of the large number of variables to explore and 
comparisons to make, and its increased risk of Type 1 errors, Bonferroni adjustments to the alpha 
level were applied (statistical significance Rand-sf36 p<.006; SIP p<.006; SCL90 p<.006; HADS p<.017; 
CIS p<.013). 
 
Results 
Response 
In total 200 invitation letters were sent. Sixty-one patients did not respond after sending two letters 
and could not be reached by phone on two subsequent attempts. Hence, we managed to contact 139 
patients, of which 26 patients responded that they were not willing to participate in this study, and 
113 patients agreed to participate. Of these 113 patients, 94 responded with an email address and a 
consent form (13 of whom did not return their consent form; six did not send an email address; See 
Figure 1). 72 Questionnaires were completed, resulting in a response rate of 52% of the patients who 
were initially contacted (72 of 139), and 77% of the patients who initially responded positively to our 
invitation (72 of 94). Demographic and clinical characteristics of the patients are summarized in Table 
1. No differences between response group (n=72) and non-response group (n=67) could be identified 
based on demographic characteristics (age and sex). Among the non-responders were more patients 
with an episodic phenotype: 48 of 67 versus 39 of 72 in the response group (p=0.04). 
The clinic-pathological diagnoses are summarized in table 1. Among the patients with a permanent 
phenotype (n=33) were 18 with CCD, three with Multi-minicore Disease (MmD), two with 
Centronuclear Myopathy (CNM), two with King-Denborough syndrome (KDS), two with Congenital 
Fibre Type Disproportion (CFTD), three with an axial myopathy, and three with a congenital 
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myopathy not otherwise specified. The episodic phenotype group (n=39) included 37 patients with 
MH, one with ERM, and one with hyperCKemia. 
 
Functional impairment (SIP) 
Functional impairment as assessed with the eight dimensions of the Sickness Impact Profile (SIP) is 
shown in Table 2. Mean scores on all dimensions reflected more functional impairments in patients 
with RYR1-related myopathies compared to healthy controls (t values varied from 3.020 (mobility: 
p=.004) to 6.277 (ambulation: p<.001), except for work (t(71)=2.417, p=.018). Compared to MELAS 
spectrum disorder patients, RYR1-mutated patients showed less impairment in mobility (t(71)=-
3.522, p=.001), social interaction (t(71)=-3.870, p<.001), alertness behavior (t(71)=-6.392, p<.001) 
and recreation (t(71)=-3.489, p=.001).  
 
Fatigue (CIS) 
On the four subscales of the CIS and its total score, RYR1-mutated patients scored significantly higher 
than healthy controls (t values varied from 3.265 (concentration: p = .002) to 9.201 (fatigue: p<.001), 
Table 2. Scores were significantly lower than MELAS spectrum disorder patients. Severe levels of 
fatigue (CIS fatigue> 35) were reported by 46% of the patients (n=33) compared to 60% in MELAS 
spectrum disorder patients. 
 
Symptoms of psychopathology  (SCL-90) 
Scores on the eight subscales of the SCL-90 revealed significant more problems compared to healthy 
controls on somatisation (t(71)=.038, p<.001. Results are summarized in Table 2. On the (total score 
of the) SCL-90, 13% of patients scored above the cut-off for high psychological distress. 
 
Mental functioning (HADS) 
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In general, patients showed no difference in levels of depression compared to MELAS spectrum 
disorder patients (t(71)=-.986, p=.327) or healthy Dutch controls (t(71)=2.166, p=.034). Scores on 
anxiety were better than those of the control group (t(71)=-2.740, p=.008) and the MELAS spectrum 
disorder patients (t(71)=-3.238, p=.002). General distress was similar to healthy controls (t(71)=.039, 
p=.969) and better than the MELAS spectrum disorder patients (t(71)=-2.389, p=.020) (Table 2). 
Looking at subgroups scoring above the cut-off, results on the HADS indicated that 21% and 17% of 
the patients experienced clinically relevant symptoms of, respectively, depression and anxiety. One 
third of the patients (33%) scored above the cut-off of clinical relevant levels of general distress.  
  
Quality of life (RAND36) 
Results from the QoL questionnaire study in RYR1-mutated patients are presented in Table 2. 
Compared to a control group of healthy individuals, RYR1-mutated patients show impairment in 
almost all QoL domains (t values varied from -5.877 (physical functioning: p<.001) to -3.142 
(experienced health change: p=.002) except for emotional role functioning (t(71)=-.199, p=.843), and 
mental health (t(71)=.278, p=.782) and pain (t(71)=-2.740, p=.008). In comparison with a sample of 
patients with a mitochondrial disease (MELAS spectrum disorder), RYR1-mutated patients experience 
a better QoL (t values varied from 3.356 (physical role functioning: p=.001) to 6.048 (general health: 
p<.001) except for equally impaired scores on physical functioning (t(71)=-.664, p=.509), pain 
(t(71)=.945, p=.348), and experienced health change (t(71)=.531, p=.597). 
 
Comparison of permanent and episodic phenotypes 
Of 72 RYR1-mutated patients, 33 patients had a permanent and 39 had an episodic phenotype. The 
permanent phenotype group experienced worse physical functioning (F(1,70)=44.6, p<.001), and 
more functioning impairments in home management (F(1,70)=9.8, p=.003), mobility (F(1,70)=7.3, 
p=.009), and ambulation (F(1,70)=39.9, p<.001). With regards to psychological functioning and 
fatigue, no differences between the groups were found. 
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Regarding QoL, compared to healthy controls patients with a permanent phenotype experienced 
lower physical (role) and social functioning, less vitality, more pain, worse general health and 
experienced health change. Regarding functional impairment, they experienced more difficulties in 
sleep/rest, home management, mobility, social interaction, ambulation, recreation. Furthermore, 
with regards to psychological functioning, these patients reported more somatisation. With regards 
to fatigue, patients reported more perceived fatigue, motivation and activity problems (t-values 
varied from 2.906 (mobility: p=.006) to -10.019 (physical functioning: p<.001). Anxiety levels were 
significantly lower than those of healthy controls (t=-4.126; p<.001). 
Patients with an episodic phenotype reported more perceived fatigue severity and motivation 
problems, more difficulties in social interaction, and more impairment in recreation and pastimes (t 
values varied from 3.206 (recreation: p=.003) to 5.447 (fatigue: p<.001) compared to healthy 
controls. Inspection of single items revealed that these patients report decreased sexual activity, 
took it slower with some of their usual activities, went out for entertainment less often, enjoyed less 
recreational activities, and dedicated themselves to hobbies for shorter periods of time.  
 
Discussion 
The present questionnaire-based study to our knowledge is the first study to systematically 
investigate the impact of RYR1-related myopathies in affected individuals, ranging from functional 
impairments and fatigue to psychological wellbeing and QoL in general. Our study showed that 
patients with RYR1-related myopathies throughout the recognized disease spectrum have more 
functional impairments and experienced chronic fatigue compared to healthy controls, with almost 
half of all patients being severely fatigued (CIS fatigue > 35). Whilst functional impairments and 
fatigue were more pronounced in those with congenital myopathy phenotypes, individuals with 
episodic phenotypes also scored higher in all relevant categories compared to healthy controls, but 
less compared to a multisystem disorder with neuromuscular involvement, MELAS. Although one 
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third (33%) of patients scored above the cut-off point for high distress, in general scores indicative of 
psychological functioning were similar compared to the normal control population. 
Findings of increased fatigue as well as impaired physical and social functioning are not unexpected 
in RYR1-related congenital myopathies (permanent phenotypes), considering the associated variable 
but often substantial weakness. However, the severity of the associated disease burden suggested by 
our study is noteworthy, considering that RYR1-related myopathies are often regarded as relatively 
mild conditions compared to other congenital myopathies. These findings are even more remarkable 
as our cohort included only adult patients, thus excluding some of the early-onset RYR1-related 
paediatric manifestations associated with even more profound weakness and disability. Our study 
also indicates specific areas of malfunctioning in individuals with RYR1-related disorders that might 
warrant further in-depth exploration, certain aspects of social interaction (such as decreased sexual 
activity), recreational activities (for example, performing such activities more slowly) and general 
problems with motivation.  
Milder but essentially similar findings in individuals with RYR1-related MH and RM suggest that these 
conditions are not purely episodic conditions, but do have a phenotype associated with a substantial 
disease burden also between episodes. The concept of RYR1-related RM exhibiting also inter-
episodic myopathic features is supported by the additional presence of (exertional) myalgia without 
demonstrable muscle breakdown in individuals with RYR1-related RM and their carrier relatives, 
initially reported by our group [5] and independently confirmed in subsequent smaller cohorts from 
Denmark and South America.[26, 27] One of these series also already suggested an effect on 
activities of daily living in patients with RYR1-related RM, something which has more systematically 
been explored in the present study, also with regards to its impact on QoL parameters. Parameters of 
physical and social functioning as well as QoL in individuals with RYR1-related MH, representing 
almost all patients with episodic phenotypes in our cohort, are here reported for the first time: these 
parameters suggest that as in patients with RYR1-related RM, patients with RYR1-related MH do also 
have a substantial disease burden in daily life, a concept that is currently not well-established. 
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Although no systematic studies have been performed yet, earlier observations in isolated families 
with RYR1-related MH suggest a high prevalence of pain, in particular affecting the lower back 
muscles [28], a muscle group that may also become manifestly weak over time in such patients.[29] 
Taken together, these observations emphasize the previous notion that RYR1-related MH and RM are 
different but closely related clinical manifestations of the same mutational spectrum, presenting 
predominantly episodically on triggering but associated with a substantial permanent disease burden 
in daily life. 
Although no detailed QoL studies have been reported in RYR1-related and other congenital 
myopathies to date, similar studies have been performed in other, mainly dystrophic neuromuscular 
disorders such as Duchenne muscular dystrophy, myotonic dystrophy type 1 (DM1) and 
facioscapulohumeral muscular dystrophy (FSHD), but also neurogenic conditions such as spinal 
muscular atrophy.[30-33] These studies may serve as a point of comparison for the present study but 
may also help to delineate specific determinants of impaired QoL in neuromuscular disorders. In 
particular, comparison with previously reported cohorts of FSHD (n=139), DM1 (n=322), and 
hereditary motor and sensory neuropathy type I (HMSN; n=137) from our centre showed a lower 
prevalence of severe fatigue (CIS fatigue≥35) in patients with RYR1-related myopathies (46% vs 61%, 
74% and 64% respectively; p=0.04; p,0.0001; p=0.01 respectively).[34] In this previous study, 
regression analyses were carried out to determine the contribution of different dimensions to fatigue 
severity.[34] The number of patients in our current study was too small to perform a similar analysis, 
however, this ought to be considered in larger prospective studies in future concerning RYR1-related 
and other congenital myopathies.  
Impairment of physical activity and muscle strength, important contributors to altered QoL in 
conditions such as FSHD and DM1 [35], are likely to have contributed to impaired QoL in RYR1-
related congenital myopathies (permanent phenotypes) but are unlikely to explain similar 
observations in RYR1-related RM and MH, considering that individuals with these episodic 
phenotypes are normally strong (or even particularly athletic). It is conceivable that the absence of 
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weakness in combination with a large muscle mass in some of these individuals may enable them to 
participate effectively in strenuous sports (personal observation), an ability that in turn might 
predispose to a higher incidence of ERM, muscle fatigue and an adverse effect on QoL. The common 
occurrence of high levels of physical fitness and reduced exercise tolerance or lower fatigue 
thresholds in some individuals with RYR1-related episodic phenotypes may reflect specific effects of 
the dominant RYR1 gain-of-function mutations typically underlying such phenotypes. Although not 
the focus of the present study, such mechanisms warrant further investigation in future, and may 
include (i) fatigue caused by continuous stimulation of SERCA activity indirectly mediated through a 
“leaky” RyR1 channel; (ii) high circulating levels of IL-6 in RYR1 mutation carriers causing chronic pain 
both at rest and during activity [36, 37]; and (iii) fear of (recurrence of) rhabdomyolysis limiting the 
motivation to exercise in some patients. From a practical point of view, it is noteworthy that the 
substantial disease burden caused by exertional myalgia and fatigue may not be immediately obvious 
in patients with RYR1-related MH, considering their lack of weakness and often athletic muscle build; 
this is something that ought to be considered.[38, 39] Therefore, counseling of these patients should 
extend beyond prevention of recurrent MH or RM episodes, and include rehabilitation focused on 
pain and fatigue. 
Considering that RYR1-related myopathies may show some multisystem features, we also compared 
RYR1-mutated patients with patients affected by MELAS, a mitochondrial multisystem disorder with 
muscle and brain features. In comparison to MELAS, RYR1-mutated patients generally have a better 
QoL, less functional impairment, less anxiety, less perceived fatigue, and are less often severely 
fatigued. This is not unexpected, considering that MELAS is a more extensive condition. A better 
example for comparison appears McArdle disease, another neuromuscular disorder with an often 
severe episodic phenotype that however has substantial permanent features, as evidenced by a 
recent questionnaire study including 81 patients, demonstrating lower clinical scores compared to 
the general population in physical domains of health-related QoL parameters.[40] 
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The main limitation of this study relates to the low response rate of 52% of patients who were 
invited to participate (or 77% of patients who had initially agreed to participate after having been 
invited), suggesting a potential selection bias. Although there were no differences in age and sex 
between the response and non-response group, the non-response group consisted of more patients 
with the episodic phenotype than the response group, suggesting that our results may be more 
reflective of the latter. In addition and non-regarding specific subgroups, more symptomatic patients 
may be more inclined to participate in such a symptom-centred questionnaire study, thus potentially 
leading to an overestimation of the severity of the associated disease phenotype. As a result of the 
cross-sectional questionnaire study design, we could not identify the causes of functional 
impairments and loss of QoL. Based on the limitations as outlined, more extensive prospective 
longitudinal studies focussing on RYR1-related myopathies will be required. 
In conclusion, the present study demonstrates that both permanent and episodic RYR1-related 
disorders are associated with a substantial disease burden, characterized by functional limitations 
and severe fatigue, and a resulting loss of QoL. As such, our study challenges the concept of RYR1-
related myopathies as relatively mild conditions, and of RYR1-related RM and MH as episodic 
conditions with no significant inter-episodic phenotypes. This study should provide the basis for 
more extensive studies investigating QoL in RYR1-related and other congenital myopathies, and alert 
physicians and multidisciplinary team members to the multiple and often hidden needs of patients 
presenting with RYR1-related RM and MH.   
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Figure 1: 1 Flowchart showing responses of patients 
Non-response group in light grey boxes on the right; response group in dark grey box. 
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Table 1. Patient characteristics 
Number and demographics of patients who participated in this questionnaire study. The number of 
patients are indicated for each phenotype. Patients were divided into i) a group with permanent 
weakness (n=33); i.e. the congenital myopathies and axial myopathy, and ii) a group with episodic 
symptoms provoked by anaesthesia, exertion or other triggers (n=39). 
 
 Total Permanent 
phenotypes 
Episodic  
phenotypes 
Number of patients 72 33 39 
Gender: Male 37 18 19 
Age: Mean (SD) 49.3 (14.2) 50.9 (14.6) 48.1 (13.9) 
Phenotype (N) CCD: 18 
MmD: 3 
CNM: 2 
KDS: 2 
CM: 3 
Axial myopathy: 3 
CFTD: 2 
MH: 37 
RM: 1 
HyperCKemia: 1 
CCD: 18 
MmD: 3 
CNM: 2 
KDS: 2 
CM: 3 
Axial myopathy: 3 
CFTD: 2 
 
 
 
 
 
 
 
MH: 37 
ERM: 1 
HyperCKemia: 1 
 
MH: Susceptible for malignant hyperthermia; RM: Exertional rhabdomyolysis; CCD: Central Core 
Disease; MmD: Multi-mincore Disease; CNM: Centronuclear Myopathy; KDS: King Denborough 
syndrome; CM: Congenital myopathy; CFTD: Congenital Fibre Type Disproportion. 
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Table 2. Results of questionnaires in RYR1-related myopathies and MELAS 
Scores from patient-reported outcome measures in RYR1-related myopathy patients compared to 
patients with MELAS spectrum disorder and control subjects from the general population, based on 
specific questionaires with separate domains. 
 
Questionnaires /  
Domain 
Mean (SD) of 
patients with RYR1-
related myopathies 
n = 72 
Mean (SD) of 
patients with MELAS 
spectrum disorder 
n = 72 
[13] 
Mean (SD) of control 
subjects in general 
population 
Functional impairment (SIP)    
Sleep / Rest 44.8 (62.1)c 50.6 (52.9) 11.4 (26.0) 
Home management 77.9 (97.6)c 86.9 (86.5) 8.8 (32.0) 
Mobility 19.0 (49.3)b,c 39.5 (93.3) 1.5 (8.7) 
Social interaction 75.8 (107.2)b,c 124.7 (142.0) 9.0 (26.9) 
Ambulation 78.3 (105.9)c 59.9 (90.6) 0.0 (0.0) 
Alertness behaviour 53.6 (97.6)b,c 127.1 (157.5) 15.4 (78.8) 
Work 27.2 (50.7) 30.9 (59.1) 12.7 (64.4) 
Recreation  49.7 (65.2)b,c 76.5 (71.7) 6.7 (21.7) 
Fatigue (CIS)    
Perceived fatigue 31.7 (13.2)b,c 37.4 (12.8) 17.3 (10.1) 
Concentration 12.0 (6.6)b,c 18.7 (9.2) 9.5 (5.9) 
Motivation 12.3 (5.6)b,c 14.8 (6.3) 7.9 (4.1) 
Activity 9.1 (5.3)b,c 11.9 (6.0) 6.6 (4.5) 
Symptoms of psychopathology  (SCL90)   
Agoraphobia 8.4 (3.2)  7.8 (1.5) 
Anxiety 12.7 (4.1)  12.5 (3.1) 
Depression 22.5 (8.3)c  20.4 (4.7) 
Somatisation 19.5 (6.7)c  16.3 (4.0) 
Obsessive-compulsive beh. 14.1 (5.3)c  12.7 (3.3) 
Interpersonal sensitivity 23.0 (6.1)  23.3 (4.8) 
Hostility 6.8 (1.3)  7.0 (1.2) 
Sleep 5.6 (2.6)c  4.8 (1.9) 
Total 123.53 (32.5)   
Mental functioning (HADS)    
Depression 4.4 (4.0) 4.9 (4.2) 3.4 (3.3) 
Anxiety 4.0 (3.4)b,c 5.3 (4.2) 5.1 (3.6) 
Total – General distress 8.4 (6.6) 10.3 (7.7) 8.4 (6.3) 
Quality of life (RAND36)    
Physical functioninga 61.0 (30.1)c 63.4 (26.7) 81.9 (23.2) 
Social functioning 76.6 (25.2)b,c 64.1 (24.3) 86.9 (20.5) 
Physical role functioninga 56.9 (43.9)b,c 39.6 (42.5) 79.4 (35.5) 
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Emotional role functioning 83.3 (33.1)b 69.4 (40.2) 84.1 (32.3) 
Mental health 77.3 (14.6)b 70.8 (17.6) 76.8 (18.4) 
Vitality 57.9 (18.6)b,c 49.0 (18.8) 67.4 (19.9) 
Pain 71.2 (25.8) 68.3 (25.9) 79.5 (25.6) 
General health 60.1 (22.5)b,c 44.1 (22.4) 72.7 (22.7) 
Experiences health change 44.4 (21.5)c 43.1 (21.1) 52.4 (19.4) 
 
a items in the physical functioning domain address essential abilities of getting about in daily life 
(walking, walking up stairs, carry shopping bags, personal hygiene and getting dressed), whereas 
physical role functioning focuses on the difficulties in daily life due to impaired physical functioning 
(difficulties in working or fulfilling household duties);  
b significant difference between RYR1-related myopathy patients and patients with MELAS spectrum 
disorder;  
c significant difference between RYR1-related myopathy patients and control subjects from the 
general population. 
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Table 3. Table 2. Results of questionnaires in permanent and episodic phenotypes of RYR1-related 
myopathies 
Scores from patient-reported outcome measures in patients with the the permanent phenotype 
compared to patients with the intermittent phenotype, and compared to control subjects from the 
general population 
 
Questionnaires /  
Domain 
Mean (SD) 
Permanent 
phenotype 
n = 33 
Mean (SD)  
Episodic  
phenotype 
n = 39 
Mean (SD) of control 
subjects in general 
population 
Functional impairment (SIP)    
Sleep / Rest 51.2 (60.6)c 39.4 (63.6) 11.4 (26.0) 
Home management 114.9 (99.7)b,c 46.6 (85.1) 8.8 (32.0) 
Mobility 35.4 (66.9)b,c 5.2 (18.4) 1.5 (8.7) 
Social interaction 93.0 (121.2)c 61.3 (92.9)c 9.0 (26.9) 
Ambulation 147.2 (111.8)b,c 20.1 (53.1) 0.0 (0.0) 
Alertness behaviour 45.6 (71.1) 60.3 (116.0) 15.4 (78.8) 
Work 34.8 (62.9) 20.7 (37.2) 12.7 (64.4) 
Recreation  61.2 (64.9)c 39.9 (64.8)c 6.7 (21.7) 
Fatigue (CIS)    
Perceived fatigue 34.4 (12.2)c 29.3 (13.8)c 17.3 (10.1) 
Concentration 11.7 (5.8) 12.3 (7.2) 9.5 (5.9) 
Motivation 12.5 (5.5)c 12.2 (5.8)c 7.9 (4.1) 
Activity 10.2 (5.3)c 8.1 (5.0) 6.6 (4.5) 
Symptoms of psychopathology  (SCL90)   
Agoraphobia 8.4 (2.9) 8.4 (3.4) 7.8 (1.5) 
Anxiety 11.9 (2.4) 13.3 (5.1) 12.5 (3.1) 
Depression 23.3 (8.6) 21.9 (8.1) 20.4 (4.7) 
Somatisation 20.0 (6.6)c 19.0 (6.9) 16.3 (4.0) 
Obsessive-compulsive 
behaviour 
14.2 (4.2) 14.0 (6.2) 12.7 (3.3) 
Interpersonal sensitivity 23.6 (6.3) 22.6 (5.9) 23.3 (4.8) 
Hostility 6.6 (1.0) 6.9 (1.5) 7.0 (1.2) 
Sleep 5.6 (2.3) 5.7 (2.9) 4.8 (1.9) 
Total 124.5 (29.4) 122.7 (35.4)  
Mental functioning (HADS)    
Depression 4.6 (4.3) 4.3 (3.9) 3.4 (3.3) 
Anxiety 3.2 (2.6)c 4.6 (3.9) 5.1 (3.6) 
Total – General distress 7.8 (6.3) 8.9 (6.9) 8.4 (6.3) 
Quality of life (RAND36)    
Physical functioninga 40.8 (23.6)b,c 78.2 (23.8) 81.9 (23.2) 
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Social functioning 73.1 (25.2)c 79.5 (25.1) 86.9 (20.5) 
Physical role functioninga 49.2 (43.1)c 63.5 (44.0) 79.4 (35.5) 
Emotional role functioning 80.8 (33.4) 85.5 (33.1) 84.1 (32.3) 
Mental health 79.5 (13.3) 75.4 (15.5) 76.8 (18.4) 
Vitality 55.3 (20.8)c 60.0 (16.5) 67.4 (19.9) 
Pain 63.9 (24.6)c 77.3 (25.5) 79.5 (25.6) 
General health 55.9 (21.2)c 63.7 (23.2) 72.7 (22.7) 
Experienced health change 39.4 (18.8)c 48.7 (22.9) 52.4 (19.4) 
 
a items in the physical functioning domain address the essential abilities of getting about in daily life 
(walking, walking upstairs, carry shopping bags, personal hygiene and getting dressed), whereas 
physical role functioning focuses on the difficulties in daily life due to impaired physical functioning 
(difficulties in working or fulfilling household duties);  
b significant difference between RYR1-related myopathy patients and patients with MELAS spectrum 
disorder;  
c significant difference between RYR1-related myopathy patients and control subjects from the 
general population. 
 
